CharlesMerrittBeasleyJr.MD(He/Him)

PubMed

• 90 citations
  Fluoxetine efficacy in menopausal women with and without estrogen replacement
  Jay D. Amsterdam, Felipe Garcia-Espana, Jan Fawcett, Frederic M. Quitkin, Fredrick W. Reimherr
  Journal of Affective Disorders. 1999-09-01
• 148 citations
  Olanzapine Versus Haloperidol Treatment in First-Episode Psychosis
  Todd M. Sanger, J.A. Lieberman, Mauricio Tohen, S. L. Grundy, Charles M. Beasley
  The American Journal of Psychiatry. 1999-01-01
• 600 citations
  Olanzapine versus placebo and haloperidol: Acute phase results of the North American double-blind olanzapine trial
  Charles M. Beasley, Gary D. Tollefson, Pierre Tran, Winston Satterlee, Todd M. Sanger
  Neuropsychopharmacology. 1996-02-01

Journal Articles

• Effect of atomoxetine on the QT interval in healthy CYP2D6 poor metabolizers.  
  Loghin C, Haber H, Beasley CM, Kothare PA, Kauffman L, April J, jin L, Allen AJ, Mitchell MI, Br J Clin Pharmacol, 1/1/2013
• Systematic decrements in QTc between the first and second day of contiguous daily ECG recordings under controlled conditions.  
  Beasley C, Benson C, Xia J, Young S, Haber H, Mitchell M, Loghin C, PACE, 1/1/2011
• Weight changes over time in adults treated with oral or depot formulations of olanzapine: a pooled analysis of 86 clinical trials.  
  Millen BA, Campbell GM, Beasley CM., J Psychopharmacol, 1/1/2011
• Suicidality and risk of suicide – definition, drug safety concerns, and a necessary target for for drug development: a brief report.  
  Meyer RE, Salzman C, YoingstromEA, ClaytonPJ, Goodwin FK, Mann JJ, Alphs LD, Broich K, Goodman WK, Greden JF, Meltzer HY, Normand SL, Posner K, Shaffer D, Oquendo MA, ..., J Clin Psychiatry, 1/1/2010
• Suicidality and risk of suicide – definition, drug safety concerns, and a necessary target for for drug development: a consensus statement.  
  Meyer RE, Salzman C, YoingstromEA, ClaytonPJ, Goodwin FK, Mann JJ, Alphs LD, Broich K, Goodman WK, Greden JF, Meltzer HY, Normand SL, Posner K, Shaffer D, Oquendo MA, ..., J Clin Psychiatry, 1/1/2010
• Early predictors of weight gain risk during treatmentwith olanzapine: analysis of pooled data from 58 clinical trials.  
  Lipkovich I, Jacobson JG, Caldwell C, Hoffman VP, Kryzhanovskaya L, Beasley CM, Psychopharm Bull, 1/1/2009
• Design and analysis considerations for thorough QT studies employing conventional (10 s, 12-lead) ECG recordings.  
  Beasley CM, Dmitrienko A, Mitchell MI, Expert Rev Clin Pharmacol, 1/1/2008
• Fluoxetine and adult suicidality revisited: an updated meta-analysis using expanded data sources from placebo-controlled trials.  
  Beasley C, Ball S, Nilsson M, et al, J Clin Psychopharmacol, 1/1/2007
• Evaluating suicidality as an adverse event in clinical trials of fluoxetine treatment for indications other than major depressive disorder.  
  Tauscher-Wisniewski S, Disch, Plewes J, Ball SG, Beasley CM, Psychol Med, 1/1/2007
• All-cause treatment discontinuation in schizophrenia during treatment with olanzapine relative to other antipsychotics: an integrated analysis.  
  Beasley CM, Stauffer VL, Liu-Seifert H, Taylor CC, Dunayevich E, Davis JM, J Clin Psychopharmacol, 1/1/2007
• Treatment-associated suicidal ideation and adverse effects in an open, multicenter trial of fluoxetine for major depressive episodes.  
  Perlis RH, Beasley CM, Wines JD, Tamura RN, Cusin C, Shear D, Amsterdam J, Quitkin F, Strong RE, Rosenbaum JF, Fava M, Psychother Psychosom, 1/1/2007
• Early symptomatic worsening during treatment with fluoxetine in major depressive disorder: prevalence and implications.  
  Cusin C, Fava M, Amsterdam JD, Quitkin FM, Reimherr FW, Beasley CM, Rosenbaum JF, Perlis RH, J Clin Psych, 1/1/2007
• Is quality of life among minimally symptomatic patients with schizophrenia better following withdrawal or continuation of antipsychotic treatment?  
  Beasley CM, Sutton VK, Taylor CC, Sethuraman G, Dossenbach M, Naber D, J Clin Psychopharmacol, 1/1/2006
• Effects of Antipsychotic Drugs on Ito, INa, Isus, IK1, and hERG: QT prolongation, atructure activity relationship and network analysis.  
  Crumb WJ, Ekins S, Darazan RD, Wikel JH, Wrighton SA, Carlson C, Beasley CM, Pharmacol Res, 1/1/2006
• Efficacy and safety of oral tadalafil in the treatment of men in Canada with erectile dysfunction: a randomized, double-blind, parallel, placebo-controlled clinical t...  
  Carrier S, Brock GB, Pommerville PJ, Shin J, Anglin G, Whitaker JS, Beasley CM, J Sexual Med, 1/1/2005
• The combined use of ibutilide as an active control with intensive ECG sampling and signal averaging as a sensitive method to assess the effects of taalafil on the huma...  
  Beasley CM, Mitchell MI, Dmitrienko AA, Emmick JT, Shen W, Costigan TM, Bedding AW, Turick MA, Bakhtyari A, Warner MR, Ruskin JN, Cantilena LR, Kloner RA, J Am Coll Cardiol, 1/1/2005
• Tadalafil improved erectile function at 24 and 36 hours after dosing: US trial.  
  Young JM, Feldman RA, Auerbach SM, Kaufman JM, Garcia CS, Shen W, Murphy AM, Beasley CM, Hague JA, Ahuja S., J of Andrology, 1/1/2005
• Absence of clinically important HERG channel blockade by three compounds that inhibit phosphodiesterase 5 – sildenafil, tadalafil, and vardenafil.  
  Sarazan RD, Crumb WJ, Beasley CM, Emmick JT, Ferguson KM, Strnat CA, Sausen PJ, E J Pharmacology, 1/1/2004
• A multicenter, randomized, double-blind, crossover study to evaluate patient preference between tadalafil and sildenafil.  
  Von Keitz A, Rajfer J, Segal S, Murphy A, Denne J, Costigan T, Lockhart D, Beasley C, Emmick J, Eu Urology, 1/1/2004
• A double-blind, randomized, placebo-controlled trial of olanzapine in the prevention of psychotic relapse.  
  Beasley C, Sutton V, Hamilton S, Walker D, Dossenbach M, Taylor C, Alaka K, Bykowski D, Tollefson G, J Clin Psychopharmacol, 1/1/2003
• Tadalafil has no detrimental effect on human spermatogenesis or reproductive hormones.  
  Helstrom WJG, Overstreet JW, Yu A, Saikali K, Shen W, Beasley, CM, Watkins VS, J Urology, 1/1/2003
• An integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: comparisons with placebo, ...  
  Carlson CD, Cavazzoni PA, Berg PH, Wei H, Beasley CM, Kane JM, J Clin Psychiatry, 1/1/2003
• Effects of intramuscular olanzapine vs. haloperidol and placebo on QTc intervals in acutely agitated patients.  
  Lindborg S, Beasley C, Alaka K, Taylor C, Psychiatry Res, 1/1/2003
• When should a trial of fluoxetine for major depression be declared failed?  
  Quitkin F, Petkova E, McGrath P, Taylor B, Beasley C, Stewart J, Amsterdam J, Fava M, Rosenbaum J, Reimherr F, Fawcett J, ChenY, Klein D, Am J Psychiatry, 1/1/2003
• Extrapyramidal symptom profiles assessed with DIEPSS: comparison with western scales in the clinical double-blind studies of schizophrenic patients treated with eith...  
  Inada T, Beasley C, Tanaka Y, Walker D, Intl Clin Psychopharmacol, 1/1/2003
• Join now to see all

Books/Book Chapters

• Olanzapine (Zyprexa): A Novel Antipsychotic 
  Chapter: Overview of the safety of olanzapine 
  Beasley C, Grundy S, Gannon K, Berg PEditors: Tran P, Bymaster F, Tye N, Herrera J, Breier A, Tollefson G.Lippincott Williams & Wilkins, Philadelphia, PA2000
• Olanzapine (Zyprexa): A Novel Antipsychotic 
  Chapter: Efficacy of olanzapine 
  Tran P. Sutton V, Beasley C, Tollefson GEditors: Tran P, Bymaster F, Tye N, Herrera J, Breier A, Tollefson G.Lippincott Williams & Wilkins, Philadelphia, PA2000
• Aptitude, Learning, and Instruction, Vol 2: Cognitive Process Analysis of Learning and Problem Solving. 
  Chapter: Complex learning processes. 
  Anderson J, Kline P, Beasley CEditors: Snow R, Federico, P Montague W.Lawrence Erlbaum and Associates, Hillsdale, NJ1980
• The Psychology of Learning and Motivation 
  Chapter: A general learning theory and its application to schema abstraction. 
  Anderson J, Kline P, Beasley CEditors: Bower G.Academic Press, New York, NY1979
• Join now to see all

Abstracts/Posters

• Potential risk factors for development of treatment-emergent suicidal ideation in the duloxetine placebo-controlled major depressive disorder database.
  Beasley CM, Disch D, Chen W, Witte M, Acharya N, Perahia D, Nilsson, M, Perlis R, Annual Meeting of the American College of Neuropsychopharmacology. Boca Raton, FL, 12/12/2009
• Treatment-resistant major depressive disorder: comparison of acute (2-week) safety endpoints after switching treatment from other antidepressants to olanzapine/fluoxet...
  Gatz JL, Jamal HH, Plewes JM, Case MG, Beasley CM, Annual Meeting of the American College of Neuropsychopharmacology. Holywood, FL, 12/7/2009
• Potential predictive factors for development of treatment-emergent suicidal ideation in the fluoxetine placebo-controlled major depressive disorder database.
  Beasley CM, Disch D, Prabhakar V, Desiah D, Tamura R, Perlis R, Neuropsychopharmacol, 1/1/2006
• Duloxetine: meta-analysis of suicidal behaviors and thoughts in clinical trials for major depressive disorder. Neuropsychopharmacol 30:Suppl 1:S97, 2005.
  Acharya NV, Rosen AS, Polzer JP, DSouza DN, Perahia DG, Cavazzoni PA, Beasley CM, Baldessarini RJ, Neuropsychopharmacol, 1/1/2005
• Does maintenance treatment with atypical antipsychotics worsen quality of lifwe among stable patients with schizophrenia?
  Beasley CM, Sutton VK, Taylor C, Sethuraman G, Dossenbach M, Naber D, Pickar D, Neuropsychopharmacol, 1/1/2005
• Overall treatment effectiveness as measured by time continuing on antipsychotic therapy.
  Beasley C, Stauffer V, Liu-Seifert H, Rock S, Mitchell C, Dunayevich E, Davis J, Breier A, Neuropsychopharmacol, 1/1/2004
• Cardiac conduction in females under intramuscular (IM) and oral olanzapine from schizophrenia clinical trials ECGs.
  Czekalla J, Beasley C, David S, Berg P, Stauffer V, Boylan C, Euro Neuropsychopharmacol, 1/1/2002
• Assessment of insulin secretory responses using the hyperglycemic clamp in normal subjects treated with olanzapine, risperidone, or placebo
  Beasley C, Sowell M, Cavazzoni P, Breier A, Steinberg H, Dananberg J, Annual Meeting of the American College of Neuropsychopharmacology. Kona, HI, 12/10/2001
• A double-blind, placebo controlled study of short-acting intramuscular olanzapine and lorazepam in acutely agitated patients with dementia.
  Jones B, Wang H, David S, Nisivoccia J, Beasley C, Feldman P, Meehan K, Annual Meeting of the American College of Neuropsychopharmacology. San Juan, PR., 12/13/2000
• Incidence and rate of treatment-emergent potential impaired glucose tolerance and potential diabetes with olanzapine compared to other antipsychotic agents and placebo.
  Beasley C, Berg P, Dananberg J, Kwong K, Taylor C, Breier A, Annual Meeting of the American College of Neuropsychopharmacology. San Juan, PR., 12/11/2000
• Cardiac ion channel blocking profile of olanzapine and other antipsychotics.
  Crumb W, Beasley C, Thornton A, Breier A, Annual Meeting of the American College of Neuropsychopharmacology. Alcapulco, Mexico, 12/13/1999
• Olanzapine vs. clozapine: an international double-blind study in treatment resistant schizophrenia.
  Beuzen J, Birkett M, Kiesler G, Tollefson G, Wood A, Beasley C, the American College of Neuropsychopharmacology. Las Croabas, Puerto Rico, PR, 12/16/1998
• The comparative anti-muscarinic-like side effect profiles of olanzapine and risperidone treatment in patients with schizophrenia spectrum psychosis.
  Basson B, Kennedy J, Tran P, Beasley C, Bymaster F, Tollefson G, the American College of Neuropsychopharmacology. Las Croabas, Puerto Rico, PR, 12/15/1998
• Adverse event profiles associated with long-term fluoxetine treatment.
  Tamura R, Michelson D, Sundell K, Beasley C, American Psychiatric Association Annual Meeting. Toronto, Canada, 6/3/1998
• The differential risk of tardive dyskinesia with olanzapine.
  Beasley C, Tollefson G, Dellva M, Tamura R, Glazer W, Morgenstern H, American Psychiatric Association Annual Meeting. Toronto, Canada, 6/2/1998
• A blinded, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol.
  Wright P, Tollefson G, Beasley C, Tamura R, Tran P, Potvin J, Schizophrenia Res, 1/1/1998
• The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentration.
  Jones B, Crawford A, Beasley C, Tollefson G, Schizophrenia Res, 1/1/1998
• What is the differential risk of tardive dyskinesia with the novel antipsychotic olanzapine?
  Tamura R, Beasley C, Dellva M, Glazer W, Morgenstern H, Tollefson G, Schizophrenia Res, 1/1/1998
• Olanzapine in the treatment of elderly patients with schizophrenia and related psychotic disorders.
  Reams S, Sanger T, Beasley C, Schizophrenia Res, 1/1/1998
• From molecule to marketplace: profile of the atypical antipsychotic olanzapine.
  Tran P, Tollefson G, Beasley C, Crawford A, Annual meeting of the American College of Neuropsychopharmacology. Kona, HI, 12/10/1997
• What is the differential risk of tardive dyskinesia with the atypical antipsychotic olanzapine?
  Beasley C, Tollefson G, Dellva M, Tamura R, Glazer W, Morgenstern H., Annual meeting of the American College of Neuropsychopharmacology. Kona, HI, 12/10/1997
• A blinded trial on the course and relationship of depressive symptoms in schizophrenia.
  Tollefson G, Sanger T, Beasley C, Annual meeting of the American College of Neuropsychopharmacology. Kona, HI, 12/8/1997
• What is the differential risk of tardive dyskinesia with the atypical antipsychotic olanzapine?
  Dellva M, Tamura R, Glazer W, Morgenstern H, Beasley C, Euro Neuropsychopharmacol, 1/1/1997
• Olanzapine versus haloperidol: analysis of schizophrenic patients from the multi-center international trial.
  Crawford A, Gomez J, Beasley C, Tollefson G, Euro Neuropsychopharmacol, 1/1/1997
• The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentration.
  Crawford A, Beasley C, Tollefson G, Euro Neuropsychopharmacol, 1/1/1997
• Join now to see all

Lectures

• A tale of two profiles: the hemodynamic effects of atomoxetine under clinical observation vs. intensive monitoring. 
  Cardiac Safety Research Consortium – Pediatric Cardiovascular Safey Drug and Medical Device Developm - 12/10/2010
• How to characterize the QT effect in the targeted patient population when a TQT study is positive. 
  DIA Conference: Cardiovascular Safety in Drug Development: QT, Arrhythmias, Thrombosis, and Bleeding - 4/12/2009
• Regulatory, procedural, and statistical considerations in the thorough QT study: the complexity of the design of a thorough QT study 
  World Pharmaceutical Congress. Philadelphia, PA - 5/12/2008
• Conduct & Design of a TQT Study. Keynote address 
  QT and Drug Development. London - 10/24/2007
• Effective strategies for designing thorough QT studies. 
  eXlpharma webinar - 9/27/2007
• Why we need improved preclinical predictors and human biomarkers for torsades de pointe. Keynote presentation, Cardiac Safety. 
  World Pharmaceutical Congress. Philadelphia, PA - 6/12/2007
• Is 36,000 ECGs overkill? 
  DIA Conference – Challenges and Practical Aspects of Assessing Clinical QT Prolongation / Proarrhyth - 5/9/2006
• Do we need a new ear, a new purse, or both? OR What do we need to more effectively and efficiently confirm the absence of risk of torsades? 
  Cardiac Safety and Critical Pathway Initiative Regulatory Think-Tank. Bethesda, MD - 10/11/2005
• Drug development from the industry perspective: challenges and opportunities. A Workshop on Clinical Trials in Psychopharmacology. 
  New York, NY - 4/12/2005
• Nomenclature for suicide-related thoughts and behaviors. American Academy of Child and Adolescent Psychiatry. 
  American Academy of Child and Adolescent Psychiatry. Washington, DC - 10/21/2004
• Prospective evaluation of insulin sensitivity by the hyperinsulinemic, euglycemic clamp in healthy volunteers treated with olanzapine, risperidone, or placebo 
  Annual Meeting of the American College of Neuropsychopharmacology. San Juan, PR - 12/11/2002
• Olanzapine. 
  British Association for Psychopharmacology Regional Meeting. Guilford, England. International Congr - 10/10/1997
• Olanzapine: atypical antipsychotic 
  American Society of Clinical Pharmacology and Therapeutics Annual Meeting. Orlando, FL - 3/21/1996
• Olanzapine clinical development: molecule to drug candidate. 
  NCDEU Annual Meeting. Orlando, FL - 6/1/1995
• Clinical trial design in depression and anxiety. 
  PMA Education and Research Institute Course Drug Development in Depression and Anxiety. Boston, MA - 3/15/1994
• Atypical antipsychotics: What are they? 
  Grand Rounds, Cleveland Clinic. Cleveland, OH - 11/4/1993
• Fluoxetine in tricyclic refractory major depressive disorder. 
  Second International Conference on Refractory Depression. Amsterdam, The Netherlands - 6/26/1992
• Fluoxetine: significance of plasma concentrations and impact on psychomotor performance. 
  Annual Lectureship in Forensic Toxicology. Annual meeting of the American Academy of Forensic Scien - 2/21/1992
• Fluoxetine: worldwide suicidality data. 
  Annual Meeting of the American College of Neuropsychopharmacology. San Juan, PR - 12/11/1991
• Strategies to lower placebo response rates in depressed patients in antidepressant trials. 
  Annual Meeting of the American College of Neuropsychopharmacology. San Juan, PR. (Study Group). - 12/9/1991
• Placebo response in depression: associated variables? 
  Annual Meeting of the American College of Neuropsychopharmacology. Maui, HI. (Study Group) - 12/13/1989
• TSH response to TRH and differential drug response in psychosis. 
  Founder’s Day Resident Award Paper Presentation, Ohio Psychiatric Association. Toledo, OH - 4/23/1988
• Medication response subtyping of psychoses and neuroendocrine correlates. 
  Indiana University Psychiatric Research Institute Seminar. Indianapolis, IN - 11/5/1987
• TSH response to TRH and drug response in psychosis. 
  Society for Biological Psychiatry Annual Meeting. Chicago, IL - 5/7/1987
• TSH response to TRH and medication response subtypes of psychoses. 
  Maurice Levine Essay Award Presentation, Cincinnati Psychiatric Society. Cincinnati, OH - 4/15/1987
• Join now to see all

Other

• Response (letter). 
  Beasley C
  Aust N Z J Psychiatry - 1/1/1999
• Fluoxetine-Dopaminergic Interaction Data (letter) 
  Beasley C
  J Clin Psychiatry - 1/1/1994
• Trend in suicide rates since fluoxetine introduction (letter). 
  Masica D, Beasley C, Kotsanos J, Potvin J
  Am J Pub Health - 1/1/1992
• Reply (letter). 
  Beasley C
  J Clin Psychopharmacol - 1/1/1992
• Fluoxetine and suicide (letter). 
  Beasley C
  BMJ - 1/1/1991
• Fluoxetine: mechanism of action (letter). 
  Fuller R, Beasley C
  J Am Acad Child Adolesc Psychiatry - 1/1/1991
• ‘Fluoxetine Overdose: A Case Report’ (letter). 
  Beasley C
  J Anal Tox - 1/1/1990
• Join now to see all